カンザス州における急性骨髄性白血病の臨床試験
カンザス州内の拠点で、急性骨髄性白血病に関する20件の研究が参加者を募集しています。
カンザス州内の都市
公式研究テキスト（英語）
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Central Care Cancer Center - Garden City, Garden City
- Central Care Cancer Center - Great Bend, Great Bend
- Veteran Administration Eastern Kansas Healthcare, Leavenworth
- 他4件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- 他1件
被験者募集中第2相
18歳〜59歳 · 全性別 · 2026/09/28更新 · NCT05554393MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Kansas Clinical Research Center, Fairway
- HaysMed, Hays
- University of Kansas Cancer Center, Kansas City
- 他7件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- 他2件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Westwood Cancer Center, Westwood
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- 他1件
被験者募集中第2相
18歳〜59歳 · 全性別 · 2026/09/22更新 · NCT05554406Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Kansas City KS-KUMC, Fairway
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06652438Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
- US-Kansas City KS-KUMC, Kansas City
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/01更新 · NCT07223814A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- 他1件
被験者募集中第1相
18歳〜75歳 · 全性別 · 2026/08/25更新 · NCT05886049Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- The University of Kansas Cancer Center, Kansas City
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/20更新 · NCT06001788Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- University of Kansas Cancer Center, Westwood
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/07/17更新 · NCT05429632A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Kansas, Westwood
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/06更新 · NCT01351545A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
- University of Kansas Medical Center Research Institute, Inc., Kansas City
被験者募集中第1相
18歳以上 · 全性別 · 2026/04/13更新 · NCT06146257Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
- University of Kansas Cancer Center, Westwood
被験者募集中第1相
18歳〜65歳 · 全性別 · 2026/03/25更新 · NCT03533816A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of Kansas Medical Center, Westwood
被験者募集中第2相
18歳〜66歳 · 全性別 · 2026/03/17更新 · NCT06859424A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- The University of Kansas Medical Center Research Institute, Fairway
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/13更新 · NCT05735184Safety of MT-401-OTS in Patients With Relapsed AML or MDS
- KU Cancer Center, Kansas City
被験者募集中第1相
65歳以上 · 全性別 · 2025/12/16更新 · NCT06552416APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
- University of Kansas, Fairway
被験者募集中第1相
18歳以上 · 全性別 · 2025/05/11更新 · NCT06634394Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- University of Kansas Cancer Center, Fairway
被験者募集中第2相
18歳以上 · 全性別 · 2025/03/07更新 · NCT02781883Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
- University of Kansas Cancer Center, Fairway
被験者募集中第1相
18歳以上 · 全性別 · 2020/06/09更新 · NCT04167696ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。